FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1333-1335 May 16, 1996 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Pedersen, T. R. Related Article Related Article by Shepherd, J. PubMed Citation

To the Editor: In the West of Scotland Coronary Prevention Study, reported by Shepherd et al. (Nov. 16 issue),¹ the net benefit of taking pravastatin (40 mg per day for five years), as compared with placebo, was a 2.2 percent reduction in the combined end points of nonfatal myocardial infarction and death from coronary heart disease or a 0.7 percent reduction in the incidence of death from cardiovascular causes. Thus, 45 men with hypercholesterolemia must be treated for five years to prevent one combined end point, and 143 men must be treated to prevent one death from a cardiac cause. . . . [Full Text of this Article]

References

Related Letters:

More on Pravastatin and Coronary Disease
Grundy S. M., Rogers S.
Extract | Full Text  
N Engl J Med 1996; 335:1239-1240, Oct 17, 1996. Correspondence

This article has been cited by other articles:

• Grundy, S. M., Rogers, S. (1996). More on Pravastatin and Coronary Disease. NEJM 335: 1239-1240 [Full Text]